



MYLAN

Quality
Pharmaceutical
Products



Mylan®

Mylan Pharmaceuticals Inc.
781 Chestnut Ridge Road
Morgantown, WV 26504
Telephone: 800-796-9526
Fax: 304-598-3232
www.mylan.com

MYLAN

HYDROXYZINE HYDROCHLORIDE TABLETS, USP 10 MG, 25 MG, & 50 MG

New Product Announcement

MYLAN PHARMACEUTICALS INTRODUCES HYDROXYZINE HYDROCHLORIDE TABLETS, USP 10 MG, 25 MG AND 50 MG[†]

| | |
|----------------------------|--|
| Compare To: | Hydroxyzine Hydrochloride Tablets, USP (Pliva) |
| Therapeutic Rating: | AB |
| Expiration Dating: | 24 months |
| ANDA Number: | 091176 |
| Product Category: | Antihistamines and Anti-anxiety agents |

[†] Please See Attached Full Prescribing Information.

| | | |
|--------------------------|---------------|---------------|
| Strength: | 10 mg | |
| Form: | Tablet | |
| Color: | Light Blue | |
| Shape: | Round | |
| Imprint (Side 1): | M | |
| Imprint (Side 2): | H10 | |
| Package Size: | 100s | 1000s |
| NDC # (0378): | 2586-01 | 2586-10 |
| Bottle Size: | 75 cc | 150 cc |
| Case Pack: | 144 | 72 |
| Inner Pack: | 12 x 12 x 100 | 12 x 6 x 1000 |
| Length: | 14.875 | 13.75 |
| Width: | 11.375 | 9.563 |
| Height: | 10.25 | 13.50 |
| Cube: | 1.00 | 1.03 |
| Weight: | 13.93 lbs. | 21.54 lbs. |
| AWP[‡]: | \$62.36 | \$623.60 |

| | | |
|--------------------------|---------------|---------------|
| Strength: | 25 mg | |
| Form: | Tablet | |
| Color: | Blue | |
| Shape: | Round | |
| Imprint (Side 1): | M | |
| Imprint (Side 2): | H25 | |
| Package Size: | 100s | 1000s |
| NDC # (0378): | 2587-01 | 2587-10 |
| Bottle Size: | 75 cc | 150 cc |
| Case Pack: | 144 | 72 |
| Inner Pack: | 12 x 12 x 100 | 12 x 6 x 1000 |
| Length: | 14.875 | 13.75 |
| Width: | 11.375 | 9.563 |
| Height: | 10.25 | 13.50 |
| Cube: | 1.00 | 1.03 |
| Weight: | 13.93 lbs. | 21.54 lbs. |
| AWP[‡]: | \$91.46 | \$914.60 |

| | | |
|--------------------------|---------------|---------------|
| Strength: | 50 mg | |
| Form: | Tablet | |
| Color: | Blue | |
| Shape: | Round | |
| Imprint (Side 1): | M | |
| Imprint (Side 2): | H50 | |
| Package Size: | 100s | 1000s |
| NDC # (0378): | 2588-01 | 2588-10 |
| Bottle Size: | 75 cc | 400 cc |
| Case Pack: | 144 | 12 |
| Inner Pack: | 12 x 12 x 100 | 12 x 1 x 1000 |
| Length: | 14.875 | 11.625 |
| Width: | 11.375 | 8.875 |
| Height: | 10.25 | 6.125 |
| Cube: | 1.00 | 0.37 |
| Weight: | 17.11 lbs. | 6.97 lbs. |
| AWP[‡]: | \$111.50 | \$1,115.00 |


[‡]AWP for a Mylan product is reported by Mylan with reference to AWP for a brand company's therapeutically-equivalent product, as reported by American Druggist, First Data Bank or another nationally recognized publication. AWP reported by Mylan, however, is not necessarily the same as the AWP that might be independently established and reported by the publisher. AWP does not take into account any discounts, chargebacks, rebates, or other reductions in price that may be provided. AWP should not be relied upon as the actual cost to the pharmacy or to the customer or consumer. AWP is subject to change at any time.

HYDROXYZINE HYDROCHLORIDE TABLETS, USP

10 mg, 25 mg and 50 mg

Rx only

DESCRIPTION: Hydroxyzine hydrochloride, USP has the chemical name of (\pm) -2-[2-[4-(*p*-Chloro- α -phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride.



$C_{21}H_{27}ClN_2O_2 \cdot 2HCl$
M.W. 447.83

Hydroxyzine hydrochloride occurs as a white, odorless powder which is freely soluble in water.

Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydroxyzine hydrochloride. Inactive ingredients include: anhydrous lactose, colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium lauryl sulfate, talc and titanium dioxide.

In addition, the 10 mg tablet contains FD&C Blue No. 1 Aluminum Lake and the 25 mg and 50 mg tablets contain FD&C Blue No. 2 Aluminum Lake.

CLINICAL PHARMACOLOGY: Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.

Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.

Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine's clinical effects are usually noted within 15 to 30 minutes after oral administration.

INDICATIONS AND USAGE: For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.

As a sedative when used as a premedication and following general anesthesia, **hydroxyzine hydrochloride tablets may potentiate meperidine and barbiturates**, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine hydrochloride tablets are not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

The effectiveness of hydroxyzine hydrochloride tablets as an anti-anxiety agent for long-term use, that is more than 4 months,

has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

CONTRAINDICATIONS: Hydroxyzine hydrochloride tablets, when administered to the pregnant mouse, rat and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine hydrochloride tablets are contraindicated in early pregnancy.

Hydroxyzine hydrochloride tablets are contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

WARNINGS: Nursing Mothers: It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

PRECAUTIONS: THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs and cautioned that the effects of alcohol may be increased.

Geriatric Use: A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

ADVERSE REACTIONS: Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature.

Anticholinergic: Dry mouth.

Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

In post-marketing experience, the following additional undesirable effects have been reported:

Body as a Whole: allergic reaction

Nervous System: headache

Psychiatric: hallucination

Skin and Appendages: pruritis, rash, urticaria

OVERDOSAGE: The most common manifestation of hydroxyzine overdose is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdose with any drug, it should be borne in mind

that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

DOSAGE AND ADMINISTRATION: For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: Adults, 50 mg to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 mg to 100 mg daily in divided doses.

For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 mg to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 mg to 100 mg in adults and 0.6 mg/kg of body weight in children.

When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.

HOW SUPPLIED: Hydroxyzine Hydrochloride Tablets, USP are available containing 10 mg, 25 mg or 50 mg of hydroxyzine hydrochloride, USP.

The 10 mg tablets are light blue film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **H10** on the other side. They are available as follows:

NDC 0378-2586-01
bottles of 100 tablets
NDC 0378-2586-10
bottles of 1000 tablets

The 25 mg tablets are blue film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **H25** on the other side. They are available as follows:

NDC 0378-2587-01
bottles of 100 tablets
NDC 0378-2587-10
bottles of 1000 tablets

The 50 mg tablets are blue film-coated, round, unscored tablets debossed with **M** on one side of the tablet and **H50** on the other side. They are available as follows:

NDC 0378-2588-01
bottles of 100 tablets
NDC 0378-2588-10
bottles of 1000 tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense in a tight, light-resistant container using a child-resistant closure.



MYLAN®

Mylan Pharmaceuticals Inc.
Morgantown, WV 26505

REVISED SEPTEMBER 2009
HYDZ:R2